Among 19 receptor kinase families identified in the human genome (Robinson et al., 2000), ALK, EGFR, MET, and RET tyrosine kinases have become targets for the treatment of NSCLC (Broekman et al., 2011). This evidence concerns the gene EGFR and non-small cell lung carcinoma.